Welcome to the Oncology Brothers podcast! In this episode, we kick off a three-part CME series focused on small cell lung cancer (SCLC). Joined by Dr. Hossein Borghaei, Chief of Thoracic Oncology at the Fox Chase Cancer Center. Together they dived into the evolving treatment landscape for SCLC, highlighting recent advancements and data from ASCO 2025.

Episode Highlights:

•⁠  ⁠Overview of the current standard of care for limited and extensive-stage SCLC.

•⁠  ⁠Discussion on the role of concurrent chemoradiation therapy and the new standard of care involving immunotherapy.

•⁠  ⁠Insights into the use of lurbinectedin in maintenance therapy and its impact on overall survival.

•⁠  ⁠Exploration of the promising results from the DeLLphi study on tarlatamab, a bispecific antibody, and its implications for treatment.

•⁠  ⁠The importance of patient selection and managing side effects in treatment decisions.

Join us as we navigate the complexities of SCLC treatment and look forward to future advancements that may improve patient outcomes.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Link to gain CME credits from this activity:

https://www.gotoper.com/courses/breaking-down-the-latest-clinical-data-for-first-line-maintenance-and-rr-sclc 

Follow us on social media:

•⁠  ⁠X/Twitter: https://twitter.com/oncbrothers

•⁠  ⁠Instagram: https://www.instagram.com/oncbrothers

•⁠  Website: https://oncbrothers.com/

#OncologyBrothers #SmallCellLungCancer #CME #ASCO2025 #LungCancer #Immunotherapy #CancerTreatment